Clinical trial · Expanded Access

Early Access Program of Lazertinib in Republic of Korea

Multi-center, Prospective, Early Access Program of Lazertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients With T790M Mutation-positive After 1st/2nd Generation EGFR TKIs Therapy to Assess the Safety and Efficacy of Real World Evidence.

NCT04829422CI-TRIAL-00056852approved for marketingClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs Therapy.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Lung Cancer	Malignant Lung Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Lazertinib 240 mg	Drug	Lazertinib	ALIAS

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 19 Years

Show eligibility criteria text

Inclusion Criteria:

* Patients aged at least 19 years
* Patients who have written consent for use of personal and medical information for the study purpose
* Patients who are prescribed and administered with approved indication for Lazerinib in Korea and not been treated with Lazertinib previously.

Exclusion Criteria:

* Patients with hypersensitivity to Lazertinib or its any ingredients
* Patients who belong to contraindication listed on lazertinib label in Korea
* Patients who are treated for an indication not approved for the use of Lazertinib
* Women who are pregnant or may possibly become pregnant

References

Publications (0)

Data not yet available

No reference posted for this study.